Sponsored diagnostic testing programs for ALG1-Congenital Disorder of Glycosylation (CDG-Ik)
ALG1-congenital disorder of glycosylation (ALG1-CDG, CDG-Ik) is a rare inherited metabolic condition caused by defects in protein glycosylation. It can lead to developmental delays, seizures, feeding difficulties, vision problems, and multi-system involvement. Genetic testing confirms the diagnosis and supports care planning and family counseling.
1 program found for ALG1-Congenital Disorder of Glycosylation (CDG-Ik)
This program provides access to genetic testing for pediatric patients under 18 who present with an unprovoked seizure. The panel evaluates key epilepsy-associated genes to support diagnostic confirmation, inform prognosis, and guide clinical management. Testing is available to eligible patients when ordered by a licensed healthcare provider.
